U.S. Surgical allowed to market ABBI

Article

The Food and Drug Administration has notified U.S. Surgical thatit will allow the Norwalk, CT, company to continue to market itsAdvanced Breast Biopsy Instrumentation (ABBI) device under theproduct's existing 510(k) application. The FDA issued a

The Food and Drug Administration has notified U.S. Surgical that

it will allow the Norwalk, CT, company to continue to market its

Advanced Breast Biopsy Instrumentation (ABBI) device under the

product's existing 510(k) application. The FDA issued a warning

letter to U.S. Surgical last month, claiming that ABBI's 510(k)

application did not include an indication for breast biopsy (SCAN

6/19/96). U.S. Surgical denied the FDA's claims. The two sides

are in negotiations to resolve any remaining issues related to

ABBI advertising and labeling, according to the company.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.